Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study - Gelmon, K A; Tischkowitz, M; Mackay, H (Lancet Oncol, 2011)